What is Musely?
Musely operates as a sophisticated digital healthcare platform specializing in personalized prescription skincare and hair treatments. By facilitating online consultations with licensed dermatology professionals, the company provides customized treatment plans for complex conditions such as acne, pigmentation, aging, rosacea, and hair loss. The platform integrates medical guidance with direct-to-consumer pharmacy fulfillment, effectively bridging the gap between clinical expertise and accessible, remote patient care. This model emphasizes individualized formulations and ongoing treatment support, positioning Musely as a leader in the intersection of technology and aesthetic medicine.
How much funding has Musely raised?
Musely has raised a total of $372.2M across 3 funding rounds:
Series A
$6.2M
Series B
$16M
Other Financing Round
$350M
Series A (2014): $6.2M with participation from DCM Ventures, GSR Ventures, and InnoSpring
Series B (2014): $16M, investors not publicly disclosed
Other Financing Round (2026): $350M supported by General Catalyst
Key Investors in Musely
General Catalyst
General Catalyst is a venture capital firm that partners with founders to build transformational businesses, providing both strategic capital and operational expertise across the healthcare and technology sectors.
DCM Ventures
DCM Ventures is a global venture capital firm that focuses on early-stage and growth-stage investments, leveraging deep industry insights to support companies in the technology and digital services markets.
GSR Ventures
GSR Ventures is a prominent venture capital firm specializing in early-stage investments, with a strong focus on technology-driven companies that demonstrate high growth potential and market disruption.
What's next for Musely?
With the successful closure of this major strategic investment, Musely is poised to accelerate its market expansion and enhance its technological infrastructure. The capital will likely be deployed to scale its pharmacy operations, broaden its range of dermatological treatments, and invest in proprietary algorithms that optimize patient outcomes. As the company moves into this next phase of development, it will focus on deepening its integration with healthcare providers and refining its user experience to maintain its competitive edge in the rapidly evolving telemedicine landscape. The strategic backing from high-profile investors provides the necessary resources to navigate the complexities of scaling a digital health enterprise while maintaining rigorous clinical standards.
See full Musely company page
